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Abstract 
  
The objective of this study was to evaluate bacterial contamination in multi-
dose veterinary medication vials in dairy and poultry farms in Khartoum 
State. A total of 324 samples of 22 veterinary medications were collected 
from 35 dairy and poultry farms. The medication types included injectable 
(antibiotic and non-antibiotic) and non-injectable drugs. Samples from 
injectable drugs constituted 96% of total number of samples. Samples were 
cultured on Blood Agar and MacConkey’s Agar plates and incubated 
aerobically at 37 oC for 48 hours. The antibiotic samples were cultured after 
being centrifuged and washed with sterile normal saline for three times to 
obtain antibiotic-free culturable sediment. Forty-one isolates from 36 
samples of 12 medications were recovered; with a contamination prevalence 
of 11.1%. No isolate was recovered from antibiotic samples (0/225). The 
contamination prevalence in non-antibiotic samples was 36.4% (36/99); in 
non-antibiotic injectables was 31.4% (27/86) and in non-sterile medications 
was 69.2% (9/13). The isolates were differentiated according to their 
microscopic, culturing and biochemical properties to the following bacterial 
species: Pseudomonas aeruginosa (3.1% of total samples), Bacillus cereus 
(2.5%), Staphylococcus aureus (2.5%), Micrococcus varians (1.5%), 
Micrococcus luteus (1.2%), Staphylococcus haemolyticus (0.6%), Neisseria 
mucosa (0.6%), Staphylococcus epidermidis (0.3%) and Staphylococcus 
auricularis (0.3%). Pseudomonas aeruginosa, Staphylococcus aureus and 
Bacillus cereus were isolated from both dairy and poultry farms; whereas 
other species were obtained only from dairy farms. The data collected with 
samples (storage conditions, opening and expiry dates of vials, sterility of 
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used syringes and others) indicated that dealing with multi-dose vials is 
much violated.  
 
To conclude, the bacterial contamination prevalence in non-antibiotic 
medications (parenteral and non-parenteral) was found to be very high, and 
serious due to isolation of known potentially pathogenic bacteria, which 
might lead to spread of serious systemic infections if injected. Violated 
storage conditions, administrating method and expiry and opening dates of 
multi-dose medication vials were observed in the visited farms and could 
justify the result.   
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 اﻟﻤﺴﺘﺨﻠﺺ
ﻓﻲ  ﻷدوﻳﺔ اﻟﺒﻴﻄﺮﻳﺔ ﻣﺘﻌﺪدة اﻟﺠﺮﻋﺔﺣﺎوﻳﺎت ا ﻓﻲأﺟﺮﻳﺖ هﺬﻩ اﻟﺪراﺳﺔ ﺑﻐﺮض ﺗﻘﻴﻴﻢ اﻟﺘﻠﻮث اﻟﺒﻜﺘﻴﺮى 
 53 ﻋﻘﺎر و 22ﻋﺪد  ﻣﻦﻋﻴﻨﺔ  423 ﺟﻤﻌﺖ  .واﻟﺪواﺟﻦ ﺑﻮﻻﻳﺔ اﻟﺨﺮﻃﻮم باﻟﺤﻠﻮ اﻷﺑﻘﺎرﻣﺰارع 
ﻋﻴﻨﺎت ﺷﻜﻠﺖ . وﻏﻴﺮ اﻟﻤﺤﻘﻮﻧﺎت (وﻏﻴﺮهﺎاﻟﻤﻀﺎدات اﻟﺤﻴﻮﻳﺔ )اﻟﻤﺤﻘﻮﻧﺎت ﺷﻤﻠﺖ اﻷدوﻳﺔ . ﻣﺰرﻋﺔ
 أﺟﺎر اﻟﺪم واﻟﻤﺎآﻮﻧﻜﻲ ﻲﻨﺎت ﻓﻰ وﺳﻄﺟﻤﻴﻊ اﻟﻌﻴ ﺖزرﻋ. ﻣﻦ اﻟﻌﺪد اﻟﻜﻠﻲ ﻟﻠﻌﻴﻨﺎت% 69اﻟﻤﺤﻘﻮﻧﺎت 
اﻟﻤﻀﺎدات اﻟﺤﻴﻮﻳﺔ ﺗﻢ ﺗﺰرﻳﻌﻬﺎ ﺑﻌﺪ ﻋﻤﻠﻴﺔ . ﺳﺎﻋﺔ 84م ﻟﻤﺪة  °73وﺣﻀﻨﺖ هﻮاﺋﻴًﺎ ﻓﻲ درﺟﺔ ﺣﺮارة 
ﺗﻢ . ﺑﻤﺤﻠﻮل ﻓﺴﻴﻮﻟﻮﺟﻲ ﻟﻠﺤﺼﻮل ﻋﻠﻰ راﺳﺐ ﺧﺎﻟﻲ ﻣﻦ أي أﺛﺮﻟﻠﻤﻀﺎد اﻟﺤﻴﻮيﻃﺮد ﻣﺮآﺰي وﻏﺴﻞ 
ﻟﻢ ﻳﺘﻢ ﻋﺰل أي  .ﻣﻦ اﻟﻌﺪد اﻟﻜﻠﻲ ﻟﻠﻌﻴﻨﺎت% 1.11 ﺑﻠﻐﺖ ﺗﻠﻮث ﺑﻨﺴﺒﺔ ﻋﺰﻟﺔ 14اﻟﺤﺼﻮل ﻋﻠﻰ 
% 4.63ﺑﻠﻐﺖ ﻧﺴﺒﺔ اﻟﺘﻠﻮث ﻓﻲ ﻏﻴﺮ اﻟﻤﻀﺎدات اﻟﺤﻴﻮﻳﺔ (. 522/0)ﺑﻜﺘﻴﺮﻳﺎ ﻣﻦ اﻟﻤﻀﺎدات اﻟﺤﻴﻮﻳﺔ 
% 2.96، ﺑﻴﻨﻤﺎ آﺎﻧﺖ (68/72% )4.13وﻓﻲ اﻟﻤﺤﻘﻮﻧﺎت ﻏﻴﺮ اﻟﻤﻀﺎدات اﻟﺤﻴﻮﻳﺔ ( 99/63)
ﺣﺴﺐ ﺧﺼﺎﺋﺼﻬﺎ اﻟﻤﺠﻬﺮﻳﺔ و اﻟﻤﺰرﻋﻴﺔ اﻟﻌﺰﻻت ﻋﺮﻓﺖ . ﻘﻮﻧﺎتﻓﻲ ﻏﻴﺮ اﻟﻤﺤ( 31/9)
، %(1.3)، اﻟﺰاﺋﻔﺔ اﻟﺰﻧﺠﺎرﻳﺔ %(5.2)اﻟﻌﺼﻴﺔ ﺳﻴﺮس  :ﺔ اﻵﺗﻴﺔﻟﺒﻜﺘﻴﺮﻳاﻷﻧﻮاع اواﻟﻜﻴﻤﻮﺣﻴﻮﻳﺔ اﻟﻰ 
، اﻟﻤﻜﻮرة اﻟﺪﻗﻴﻘﺔ اﻟﻤﺘﺒﺎﻳﻨﺔ %(2.1)، اﻟﻤﻜﻮرة اﻟﺪﻗﻴﻘﺔ اﻟﺼﻔﺮاء %(5.2)اﻟﻤﻜﻮرة اﻟﻌﻨﻘﻮدﻳﺔ اﻟﺬهﺒﻴﺔ 
، اﻟﻤﻜﻮرة اﻟﻌﻨﻘﻮدﻳﺔ %(6.0)، اﻟﻤﻜﻮرة اﻟﻌﻨﻘﻮدﻳﺔ ﺣﺎﻟﺔ اﻟﺪم %(6.0) ﻃﻴﺔاﻟﻤﺨﺎ ﺴﻴﺮﻳﺔﻴ، اﻟﻨ%(5.1)
اﻟﺰاﺋﻔﺔ و ﻋﺰﻟﺖ اﻟﻌﺼﻴﺔ ﺳﻴﺮس%(. 3.0)و اﻟﻤﻜﻮرة اﻟﻌﻨﻘﻮدﻳﺔ اﻟﺒﺸﺮوﻳﺔ %( 3.0) اﻷذﻧﻴﺔ
 ﻋﺰﻟﺖ ﺑﻘﻴﺔ ، ﺑﻴﻨﻤﺎ و اﻟﺪواﺟﻦ اﻟﺰﻧﺠﺎرﻳﺔ واﻟﻤﻜﻮرة اﻟﻌﻨﻘﻮدﻳﺔ اﻟﺬهﺒﻴﺔ ﻣﻦ ﻋﻴﻨﺎت ﻣﺰارع اﻷﺑﻘﺎر
ﺟﻤﻌﺖ ﺧﻼل هﺬﻩ اﻟﺪراﺳﺔ ﻣﻌﻠﻮﻣﺎت ﻋﻦ ﻇﺮوف ﺗﺨﺰﻳﻦ اﻷدوﻳﺔ،  .ﻓﻘﻂ  اﻷﺑﻘﺎرﻣﻦ ﻣﺰارع  اﻷﻧﻮاع
ﺗﺎرﻳﺦ ﻓﺘﺢ ﺣﺎوﻳﺎﺗﻬﺎ وﺻﻼﺣﻴﺘﻬﺎ، ﺣﺎﻟﺔ اﻟﺤﻘﻦ اﻟﻤﺴﺘﺨﺪﻣﺔ وﻣﻌﻠﻮﻣﺎت أﺧﺮى وﻗﺪ آﺎﻧﺖ آﻠﻬﺎ ﻣﺨﺎﻟﻔﺔ 
  .                                                                                        ﻟﻠﻤﻌﺎﻳﻴﺮ اﻟﺼﺤﻴﺤﺔ
                                                                           
وﺗﻌﺘﺒﺮ  ﻧﺴﺒﺔ اﻟﺘﻠﻮث ﻓﻲ اﻟﻤﺤﻘﻮﻧﺎت ﻣﻦ ﻏﻴﺮ اﻟﻤﻀﺎدات اﻟﺤﻴﻮﻳﺔ ﻋﺎﻟﻴﺔ ﺟﺪًا أن إﻟﻲﺧﻠﺼﺖ اﻟﺪراﺳﺔ 
ﺧﻄﻴﺮة ﻧﺴﺒﺔ ﻟﻮﺟﻮد ﺑﻜﺘﻴﺮﻳﺎ ﻣﻌﺮوﻓﺔ ﺑﺄﻧﻬﺎ ﻣﻤﺮﺿﺔ واﻟﺘﻲ رﺑﻤﺎ ﺗﺆدي إﻟﻲ ﻧﺸﺮ إﺻﺎﺑﺎت ﺟﻬﺎزﻳﺔ 
هﺬﻩ اﻟﻨﺘﻴﺠﺔ ﻳﻤﻜﻦ ردهﺎ إﻟﻲ ﻋﺪم اﻟﺘﺨﺰﻳﻦ اﻟﺴﻠﻴﻢ ﻟﻸدوﻳﺔ، ﻃﺮﻳﻘﺔ إﻋﻄﺎﺋﻬﺎ وﻋﺪم . ﺖﺧﻄﻴﺮة إذا ﻣﺎ ﺣﻘﻨ
                           .اﻻهﺘﻤﺎم ﺑﺘﺎرﻳﺦ اﻟﺼﻼﺣﻴﺔ و ﻓﺘﺢ اﻟﺤﺎوﻳﺔ واﻟﺘﻲ ﻟﻮﺣﻈﺖ ﻓﻲ ﻣﻌﻈﻢ اﻟﻤﺰارع
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INTRODUCTION 
 
A hazardous drug is considered to be any pharmaceutical agent with the 
potential to cause increased risk, developmental or reproductive toxicity, or 
target organ effect in animals or humans. Drugs that are exposed to flood or 
unsafe municipal water or mishandled may become contaminated, which 
may lead to diseases that can cause serious health effects (Jonathan and 
Perlin, 2004). Contamination of a multi-dose vial was hypothesized to occur 
after a single syringe is used to inject an infected patient with medication, 
and the same syringe subsequently is used to withdraw additional 
medication from the multi-dose vial. If the contaminated multi-dose vial is 
used for another patient, an iatrogenic infection may spread. Laboratory 
study of this injection technique found that viral plaque-forming units could 
be transmitted to a multi-dose vial in this manner (Plott, 1990). A survey of 
100 fellows of the American Academy of Dermatology from the United 
States found that 24% of the respondents used this potentially unsafe 
procedure. The potential for iatrogenic infection by the human 
immunodeficiency virus and hepatitis B virus was described (Plott, 1990). 
Also, Pseudomonas aeruginosa, Staphylococcus aureus, S. marcescens, K. 
pneumoniae, group A Streptococcus, E. cloacae and C. albicans were 
reported as contaminants in multi-dose vials (Mattner and Gastmeier, 2004; 
Bennett et al., 1995).  
 
Many disease outbreaks and individual cases were reported in human 
medicine due to intake of contaminated medicines from multi-dose vials 
(Kirschke et al., 2003; Thompson et al., 2009; Bennett, et al. 1995). 
However, in veterinary medicine, only two reports were found; one from 
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Canada (Sabino and Weese, 2006) and the other from America (Betbeze et 
al., 2007). Authors of the former mentioned that their study was the first in 
veterinary medicine. They found a contamination prevalence of 18% 
(16/88). The second study investigated bacterial contamination in only three 
multi-dose ophthalmic solutions. 
 
Contamination of drugs should be monitored carefully in their original 
containers in the ideal setting; capsules, tablets, liquids in containers with 
screw-caps, snap lids, or droppers, and should be discarded if they are 
contaminated. All multi-dose vials should be visually inspected for 
contamination or deterioration prior to each use. Multi-dose vials are 
discarded upon the expiration date or when contamination is suspected. In 
case of many preparations, refrigeration is important, however, some multi-
dose vials are refrigerated only if specified by the manufacturer (Pharmacy 
Pearl, 2003). 
 
There are several ways that particles or bacteria can get into medicine, apart 
from manufacturer error. For example; the syringe can push particles, 
including bacteria. Foreign particles can be injected during drug 
reconstitution or during dosing. It was suggested that the best solution 
available to avoid the contamination of drugs is the usage of single dose 
vials (Kelly, 1984; Plott, 1990). 
 
In this country, the ideal storage conditions, expiry dates, proper handling 
and visual inspection for contamination or deterioration prior to each use of 
veterinary medical preparations, usage of always sterile syringes and 
marking of opening dates are not strictly considered in animal farms. This 
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can be attributed to poor knowledge and practice of hygienic measures, poor 
infra-structure and low income. 
Transmission of microorganisms via contents of pharmaceutical multi-dose 
vials and causing of diseases is well documented in human medicine, but, 
with the exception of only two reports from the world, this important type of 
investigation was not found tackled before in veterinary medicine.  
 
Objectives: 
1. To test for the presence of bacterial contamination in open multiple-dose 
veterinary medical preparations and its prevalence.  
2. To isolate and identify the aerobic bacteria in samples from different 
formulations of multiple-dose veterinary medical preparations.  
3. To conduct antibiotic sensitivity test for any bacteria found contaminating 
any antibacterial agent to confirm its resistance to it. 
4. To give a judgment on the pathogenic potential of the isolated bacteria.  
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CHAPTER ONE 
LITERATURE REVIEW  
 
1.1 Veterinary medication 
A veterinary medicinal product means any substance or combination of 
substances presented for treating or preventing disease in animals or which 
may be administered to animals with a view of making a medical diagnosis 
or to restore, correct or modify physiological functions in animals (Bishop, 
2005). 
 
1.2 Drug manufacturing 
The manufacturing processes should meet the requirements of Good 
Manufacturing Practice, especially with regard to cross-contamination (The 
International Pharmacopoeia, 1977). 
 
1.2.1 Good Manufacturing Practices (GMPs) 
Pharmaceutical substances and dosage forms, as described in a monograph 
of the International Pharmacopoeia, should be manufactured according to 
the requirements of Good Manufacturing Practices (GMP), whether those 
recommended by the World Health Organization or those laid down by a 
competent national (regional) authority in the country of manufacture. The 
processes, premises, equipment, and installations should also comply with 
the provisions of the product licence or marketing authorization, relevant 
regulation and, in the case of products destined for export, with any binding 
international norms that would affect their entry into the market. In many 
cases, this compliance can not be verified by analysing a sample of the final 
product against a pharmacopoeial monograph. The national authority will 
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need to ensure that these instructions have been followed by any means at its 
disposal, including use of appropriate certificates, inspection of the 
manufacturing site or testing of samples beyond specifications (The 
International Pharmacopoeia, 1977). 
 
1.2.2 Good practices in quality control 
Quality control is a part of GMP concerned with sampling, specifications, 
testing, organization, documentation and release procedures which ensure 
that the necessary and relevant tests are actually carried out and that 
materials are not released for use, nor products released for sale or supply, 
until their quality has been judged to be satisfactory. Quality control is not 
confined to laboratory operations but must be involved in all decisions 
concerning the quality of the product. The independence of quality control 
from production is considered fundamental. 
 
1.3 Contamination of medication 
It is the undesired introduction of impurities of a chemical or 
microbiological nature, or of foreign matter, into or onto a starting material 
or intermediate during production, sampling, packaging or repackaging, 
storage or transport (WHO, 2003). 
 
1.3.1 Cross-contamination and its avoidance 
It is the contamination of a starting material, intermediate product or finished 
product with another starting material or product during production. Cross- 
contamination should be avoided by taking appropriate technical or 
organizational measures, for example: 
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 1. Carrying out production in dedicated and self-contained areas (which 
may be required for products such as penicillins, live vaccines, live bacterial 
preparations and certain other biologicals); 
 2. Conducting campaign production (separation in time) followed by 
appropriate cleaning in accordance with a validated cleaning procedure; 
3.  Providing appropriately designed airlocks, pressure differentials, and air 
supply and extraction systems; 
 4. Minimizing the risk of contamination caused by recirculation or re-entry 
of untreated or insufficiently treated air; 
5. Wearing protective clothing where products or materials are handled; 
6. Using cleaning and decontamination procedures of known effectiveness; 
7. Using a “closed system” in production; 
8. Testing for residues; 
9. Using cleanliness status labels on equipment. 
Measures to prevent cross-contamination and their effectiveness should be 
checked periodically according to standard operating procedures. 
 Production areas where susceptible products are processed should undergo 
periodic environmental monitoring (e.g. for microbiological monitoring and 
particulate matter where appropriate). 
 
1.3.2 Sanitation and hygiene 
A high level of sanitation and hygiene should be practiced in every aspect of 
the manufacture of drug products. The scope of sanitation and hygiene 
covers personnel, premises, equipment and apparatus, production materials 
and containers, products for cleaning and disinfection, and anything that 
could become a source of contamination to the product. Potential sources of 
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contamination should be eliminated through an integrated comprehensive 
programme of sanitation and hygiene (WHO, 2003). 
 
 1.3.3 Stability and sterility of medications 
Several factors affect the stability and sterility of medications. These include 
the particular drug, the presence of a bacteriostatic or preservative agent, the 
solution used for admixture (if any), potential for contamination during the 
process, attention to aseptic technique, the storage conditions and the 
chemical stability of the compound. Given favorable growth conditions, 
many bacteria enter a "log" growth phase after about 24 hours, which 
markedly increases the contaminant concentration. Drawing up medications 
as close as possible to the time of administration will help minimize the 
potential for significant bacterial growth or endotoxin formation (Arduino et 
al., 1991). 
  
1.4. Expiration date for medications 
The expiration date on a medication is the date until which the manufacturer 
can guarantee its safety and full potency. Proper storage can help ensure that 
the medication does not “go bad.” In fact, medications stored under proper 
conditions may retain all or much of their potency for at least one to two 
years following their expiration date, often longer. However, since some 
medications become harmful if taken after they have expired, it is never 
recommended to take expired medication. 
Medications stored under adverse conditions, such as heat, humidity, and 
direct light, may actually expire before the stated expiration date. Those 
conditions can cause a medication to break down, lose its potency, or in 
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some cases become toxic. On the other hand, a refrigerator is ideal for 
certain medications and supplements: It’s cool, dark, and dry.  
According to the Food and Drug Administration (FDA), drug manufactures 
are required to indicate an expiration date or shelf life date, basically 
because there is little assurance that a medication given after this regulatory 
date will continue to be effective or safe. 
  
1.5. Medication storage temperature 
Environmental controls play a key role in maintaining drug quality. 
Temperature is one of the most important parameters to control. All drugs 
should be stored according to conditions described on the label. When 
specified on the label, controls for humidity, light, etc. should be in place. 
Temperatures should be controlled and monitored using calibrated 
monitoring devices and records of temperature and alarms, were applicable, 
should be maintained. Monitoring is conducted at points representing the 
extremes of the temperature range based on temperature mapping (Health 
Canada Guidance document, 2005). 
 
1.6 Antibiotic resistance  
The  use  of  antibiotics  in  veterinary  practice started  soon  after  it  
became  available  for  the treatment  of  human  diseases  in mid  1940s. 
Use of penicillin was started before World War II to treat mastitis.  
Antibiotic  resistant  strains  of  bacteria  were  recognized  in  the  late  
1950s  and became evident that microorganisms resistance to one  or  more  
antibiotics  can  transfer  it  to  other bacteria  (Stalheim,  1987).  The  
problem  of antimicrobial  resistance  has  become  common today,  
especially  in  the  area  of  bacterial chemotherapy  (Nandivada  and  
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Amyes,  1990). The wide spread use of antibiotics  in  humans  and  animals  
has  been followed by  the  increased emergence of bacteria resistance  to  
these  antibiotics,  particularly  in Enterobacteriaceae  (Prescott  and Baggot,  
1993). A  casual  relationship  between  increased  use  of antibiotics  and  
increased  prevalence  of  resistant bacteria has been demonstrated 
(Holmberg et al., 1987).  Transmission  of  resistance  has  been reported  
from  person  to  person  (Linton  et  al., 1972),  animal  to  animal  and  
animal  to  person  (Levy  et  al.,  1976).  Diseases  caused  by  drug-resistant  
strains  of  bacteria  may  transfer  their resistance  to  the  drug  susceptible  
strains  of bacteria  that  ultimately  may  act  as  reservoir  of resistance  to  
pathogenic  organisms.  Thus,  the presence  of  antibiotic  resistant  bacteria 
as live contaminants in antibiotics  is  a great  concern  in  both  human  and  
animal medicine. 
   
1.7 Multi-dose preparations  
The use of multi-dose containers for parenteral medications and saline 
solutions is widespread in veterinary medicine, largely based on 
convenience and cost-effectiveness. However, iatrogenic contamination of 
these items and subsequent injection into a patient is a concern. With  every 
withdrawal  from  a multi-dose  container, there  is  the  potential  for  
inadvertent  inoculation  of  the remaining contents with microorganisms 
from  the bottle top  or  contaminated withdrawal  items.  In human 
medicine, it has been demonstrated that potentially pathogenic 
microorganisms can survive and sometimes proliferate in multi-dose vials 
(MDVs) (Highsmith, 1982), thereby creating a potential risk for parenteral 
inoculation of pathogenic organisms (Nakashima, 1987). Contaminated 
MDVs have been implicated in individual cases and outbreaks of 
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nosocomial bacterial, viral, or fungal infections (Kirschke, 2003). The 
ongoing reports in the United States of hepatitis B and C transmission to 
patients and outbreaks of bacterial infections associated with unsafe 
injection practices (Thompson, 2009) is an indication that diligence is 
needed to assure that these preventive practices are being scrupulously 
followed in all healthcare settings. 
 
1.7.1 Precautions with multi-dose vials 
If aseptic technique is used consistently, an uncontaminated multidose vial 
may be used until the manufacturer's expiration date. If suspected or visible 
contamination has occurred or if sterility is questionable, the vial should be 
discarded. Each time a multidose vial is entered; aseptic technique should be 
used, including cleaning the rubber stopper with alcohol and using a sterile 
needle and syringe.  
Multi-dose vials can be contaminated when, for example:  
1. An unsterile needle is inserted into the vial. 
2. A needle is left in the vial for multiple redraws. 
3. The vial septum is allowed to come into contact with liquids. 
4. Prepared in a contaminated area. 
5. A contaminated syringe is re-used.   
These risks are increased if the vial does not contain a preservative, such as 
thiomersal, to prevent microbial growth.   
 The potential avenues for contamination of multi-dose vials and/or 
transmission of infectious agents can be overcomed by careful adherence to 
appropriate infection control protocols.  
These are well documented in both Australian and international guidelines. 
Although the Australian Drug Evaluation Committee (ADEC) of the 
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Therapeutic Goods Administration (TGA) has declined registration for 
pharmaceuticals presented in multi-dose vials on several occasions, it has 
also stated that there are special circumstances where their use is appropriate 
and can meet registration requirements (Australian Drug Evaluations 
Committee, 2005). These infection prevention practices should prevent cross 
contamination, transmission and outbreaks of infection due to unsafe 
injection, infusion and medication handling, and preparation and 
administration practices. 
 
1.7.2 Recommended protocol when using MDVs 
1. Record the date of opening on the MDV vial.  
2. Use a new sterile syringe and administration needle for each patient.   
3. Use a new drawing up needle when the MDV needs to be accessed (never 
use a used syringe to withdraw from the MDV).  
4.  Wipe the diaphragm of MDVs with 70% alcohol swab before inserting a 
new sterile needle for the extraction of a new dose (s) from a MDV   
5. Discard contents of MDV if:   
a. Sterility breached.  
b. Expiry date reached.  
c. More than a week since date of first opening, or maximum allowed time if 
longer (Infection Control Guidelines, 4th Edition Section 2 Chapter 3 pages 
30-31). 
 
1.8 Contamination of syringes and Multi-dose vials                                                               
Bacteriological studies of multi-dose vials or syringes may not be useful in 
documenting contamination, as contained bacteriostatic agents rapidly 
eliminate bacteria (Bawden et al., 1982). However no preservative that is 
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effective against all types of bacteria (Mattner and Gastmeier, 2004) and 
resistance to some of these bacteriostatic agents as well as manufacturer’s 
error is expected. In addition, contaminating pathogens are able to survive in 
MDVs for approximately two hours before the preservative takes full effect. 
It is possible that endotoxin survive even after the preservative inactivates 
the organism (Wilson et al., 1998). There is no evidence that bacteriostatic 
agents will destroy all introduced pathogenic virus and manufacturers 
recommend that only sterile equipment is used to enter multidose vials. 
  
1.9 Transmission of infection with multi-dose vials 
Depending on degree of faulty aseptic technique, studies have demonstrated 
that the bacterial contamination rates of multiple-dose vials vary 
significantly (Plott et al., 1990). In response to a report of two patients who 
died of meningitis caused by Pseudomonas aeruginosa in a German hospital 
in July 2001, Mattner and Gastmeier (2004) conducted a one-day prevalence 
study to investigate the use and contamination of MDVs. All MDVs used in 
a tertiary-care hospital that particular day were collected and tested for 
sterility. The results revealed poor compliance with infection control 
practices, including labeling of vials and maintenance of proper 
temperatures for storage. The contamination prevalence rate was determined 
to be 0.9%. 
Reports describing nearly 30 outbreaks of illness associated with MDVs 
occurring between 1983 and 2002 have been published in the scientific 
literature (Bennett et al., 1995). Pathogens responsible for the outbreaks 
included viruses (HIV, hepatitis B, and C), bacteria (E. cloacae, S. 
marcescens, S. aureus, K. pneumoniae, group A Streptococcus, and P. 
aeruginosa), and yeast (C. albicans). 
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Certain types of medications are more likely to be associated with outbreaks 
than others. Lipid containing medications such as propofol are the most 
commonly reported culprits, followed by preservative-free solutions. It is 
interesting that the preservatives utilized in vaccine MDVs do not appear to 
interrupt short-term bacterial contamination (Stetler et al., 1985); however, 
they are quite effective in the preservation of heparin and insulin (Tarr et al., 
1991).  
 In the early 1980s, Alter and her colleagues were notified of an outbreak of 
hepatitis B virus infections in a hemodialysis center in California. Because 
all infections appeared to occur within a relatively short period of time, a 
common-source exposure was suggested. The findings of their case-
controlled study demonstrated that all infected patients received drug from 
an MDV of local anesthetic (bupivacaine) (Alter et al., 1983).  
 
1.10 Medications management in dairy farms 
1.10.1 Storage facilities for livestock medicines 
Provision of a facility specifically set for storage of livestock medicines will 
improve medication effectiveness and reduce treatment errors. The ideal 
location for a storage unit is a clean, dry, frost-free area such as a farm office 
or utility room. The storage unit should protect products from changes in 
temperature, sunlight, dust, moisture, animals and insects. Products should 
be protected from temperature extremes and fluctuations as these may alter 
the products' chemical structure and reduce potency, shelf life and safety. An 
example of products affected by incorrect storage temperature is teat dips 
containing the disinfectant chlorhexidine. These products may irritate teat 
skin if used after freezing and thawing has occurred. Vaccines containing 
modified live organisms will have markedly reduced effectiveness if stored 
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at room temperature. Most antibiotic preparations are heat sensitive. These 
products should be stored in a refrigerator at a temperature between 2° and 
8° C to maintain potency. Many other products require storage in a cool 
(below 15° C) but non-refrigerated location. Product labels will indicate an 
acceptable storage temperature. Product decomposition may result from 
exposure to light. Manufacturers package light sensitive products like the 
injectable tetracyclines in light resistant containers such as colored glass 
bottles. This reduces the loss of potency due to light.  These and other 
products should be stored in a light proof storage unit. To prevent treatment 
errors, products approved for use in lactating (milking) cows should be 
stored on a separate shelf in the storage unit from those for dry cows. 
Shelves must be labeled to help maintain an organized storage unit. Products 
other than antibiotics, such as wound dressings and injectable vitamins, 
should be stored on a third shelf along with needles and other instruments 
used in the treatment of animals. Separate storage cabinets for each group of 
products will further reduce the chance of errors in product selection. 
Storage units should be locked to prevent access by children or unauthorized 
persons (Canadian Compendium of Veterinary Pharmaceuticals, Biologicals 
and Specialities, 1991). 
1.10.2 Managing livestock medicine inventory 
Careful management of the drug inventory on the farm insures that drugs are 
purchased as needed. Fresh supplies will be readily available when needed. 
This will reduce costs resulting from drug wastage. Anticipation of a time of 
increased drug use may allow the producer to take advantage of sales while 
insuring supplies are on hand. For example, the numbers of cows requiring 
treatment at dry off during a given time period can be estimated in advance. 
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Purchase of dry cow treatment products in the volume required at one time 
may be convenient and result in price reductions for bulk purchases. The 
drug inventory on the farm can be managed using the following procedures: 
1. Drugs should be purchased in quantities which will be used in a 
reasonable amount of time;  
2. Expiry dates of products should be checked before purchase;  
3. Drug cabinet should be cleaned and reorganized regularly;  
4. Products with older dates should be used first; and  
5. All expired products should be discard. 
  
1.10.3 Disposal of livestock medicines 
Safe disposal of livestock medicines is essential to protect farm employees, 
family members, untreated livestock and the environment from accidental 
exposure to potentially hazardous chemicals. 
Expired livestock medicines can be disposed of by returning them to the 
supplier. Increasingly, many veterinarians and manufacturers are willing to 
accept returns of products at the location of purchase. In some municipalities 
medicines can be disposed of on "Household Hazardous Waste Days".  
1.11 Microbial limit and sterility tests 
Before MDVs being opened and exposed to different sources of 
contamination, a manufacturer’s error that can permit for microbial 
contamination is expected. However, all medicines are usually examined for 
microbial contamination according to certain specifications that were 
included in drug pharmacopoeias, such as USP and BP. Of course sterile 
products after being cultured on enriched media under appropriative 
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conditions should be free from any bacteria or fungi. For the non-sterile 
finished products, their cultures should be free from any potential pathogen, 
but harmless organisms are permitted when their number per milliliter or 
gram of finished product is below the set limit. 
 
 
 
 
29
CHAPTER TWO 
MATERIALS AND METHODS 
 
2.1 Samples 
This study was designed to collect samples from pharmaceutical multi-dose 
veterinary preparations in dairy cattle and poultry farms so as to test for 
presence of contamination, bacterial types and their importance. 
 
2.1.1 Source of samples and time of collection 
Samples of this study were collected from a total of 35 animal farms from 
various areas of Khartoum State during the period from August 2008 to June 
2010. Animal farms were 30 dairy cattle farms and 5 poultry farms. 
Locations of farms in the state are shown in Table 1. 
 
2.1.2 Sample size 
In total, 324 samples from multi-dose veterinary medical preparations were 
collected; 303 were from dairy cattle farms and the rest were from poultry 
farms. Distribution of samples according to location of farms is shown in 
Table 1. 
 
2.1.3 Sample types 
Different pharmaceutical formulations were sampled. The sampled 
formulations were: injectable solutions, injectable suspensions, oral 
solutions, oral suspensions and topical solutions. Allotment of samples in 
relation to formulation types is presented in Table 2. The collected samples 
were from 22 medication types (Table 3). 
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 2.1.4 Sample collection method 
All preparations were well mixed before being sampled and then rubber 
stoppers were swabbed with 70% alcohol. Injectable solutions or 
suspensions and oral solutions were taken as about 10 ml volumes in 10-ml 
sterile syringes, which were then covered and wrapped with adhesive tape. 
The oral suspensions were collected in sterile bottles, as about 5-10 ml 
volumes. Each sample was labeled with a specific serial number. The 
detailed labeling of this number was recorded in a separate questionnaire 
sheet for each sample (see appendix). Details of each sample were: farm 
location, farm type and size, managing system, drug formulation, date of 
opening MDV, expiry date, storage place and condition. Other few details 
are shown in the questionnaire form. After labeling, samples were put into a 
thermos flask containing ice. Samples were then transported to the 
Microbiology Laboratory of the Faculty of Veterinary Medicine, University 
of Khartoum for bacteriological investigation. In the laboratory, samples 
were kept refrigerated before being processed. 
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Table 1. Allotment of multi-dose veterinary medical preparation                                        
samples according to location of animal farms   
Main location Sub-location 
No. of farms No. of samples 
Dairy Poultry 
Dairy 
farms 
Poultry 
farms 
Khartoum 
province 
Soba 2 0 15 0 
Alkalakla 1 0 7 0 
Taiba Elhasnab 1 0 11 0 
El Shigailab 1 0 6 0 
Khartoum 
North 
province 
Hilat Koko 
Mahlab 2 
4 0 47 0 
Hilat Koko 
Mahlab 3 
5 0 54 0 
Koko Alhila 2 0 21 0 
El Shigla 1 0 18 0 
El Giraif 1 0 7 0 
Ed Babiker 3 0 33 0 
El Silait 5 0 55 0 
Al Halfaya 0 2 0 11 
Shambat 0 1 0 2 
El Saggai 0 2 0 8 
Wad Hosona 1 0 3 0 
El Hag Yousif 1 0 10 0 
El Gadesia 2 0 16 0 
Total  30 5 303 21 
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Table 2. Distribution of multi-dose veterinary medical preparation      
samples relating to drug formulation and animal farm types 
 
Drug formulation  Dairy cattle farms Poultry farms Total 
Injectable solutions 244 0 244 
Injectable suspensions 47 0 47 
Oral solutions 0 21 21 
Oral suspensions 11 0 11 
Topical solutions 1 0 1 
Total 303 21 324 
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Table 3. Distribution of multi-dose veterinary medical preparation 
samples according to medical purpose, drug name and 
formulation  
 
Medication 
type 
Name 
 of drug Formulation 
No. of collected 
samples 
Dairy 
farms 
Poultry 
farms Total
Antiparasitics 
Albendazole Oral suspension 9 0 9
Levamisole Oral solution 0 1 1 
Ivermectin Injectable /oral solution 7 4 11 
Nitroxinil Injectable solution 5 0 5
Tetramizole Injectable solution 5 0 5 
Total     26 5 31 
Vitamins Vitamin B-complex Injectable solution 12 0 12
 Multi-vitamins Oral solution 0 16 16 
Total  12 16 28
Anti-
inflammatories  
Dexamethasone Injectable solution 8 0 8 
Phenylbutazone Injectable solution 15 0 15 
Total   23 0 23
Antibiotics 
Amoxycillin Injectable suspension 19 0 19 
Ampicillin Injectable suspension 3 0 3 
Procaine penicillin  Injectable suspension 25 0 25 
Enrofloxacin Injectable solution 29 0 29 
Gentamicin Injectable solution 15 0 15
Oxytetracycline Injectable solution 71 0 71 
Sulfadimidine Injectable solution 23 0 23 
Tylosin Injectable solution 40 0 40
Total     225 0 225 
Antihistamines Diphenylhydramine Injectable solution 1 0 1 
Antipyretics Dipyrone Injectable solution 7 0 7 
Anaesthetics Xylocaine Injectable solution 5 0 5
Metabolic 
diseases drugs 
Calcium -
borogluconate Injectable solution 1 0 1 
Anti-bloat Methyl silikon Oral suspension 2 0 2 
Disinfectants Hydrogen -peroxide 
Topical solution 1 0 1 
Total   303 21 324 
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2.2 Bacteriological investigation   
2.2.1 Asepsis and sterilization 
2.2.2 Red heat 
It was used to sterilize wire loops, needles and spatulas by holding them 
over Bunsen burner flame until they became red. 
 
2.2.3 Hot air oven 
It was used to sterilize glassware such as test tubes, graduated pipettes, 
flasks and forceps. The holding period was one hour and the oven 
temperature was 160oC. 
 
2.2.4 Moist heat (autoclaving) 
Autoclaving at 121oC for 15 minutes was used for sterilization of media and 
plastic ware. Autoclaving at 115oC for 10 minutes was used for sterilization 
of some media such as sugar-containing media. 
 
2.2.5 Irradiation 
Ultraviolet (UV) irradiation for 20 minutes was used to sterilize media 
pouring room. 
 
2.2.6 Disinfection 
Phenol and 70% alcohol were used for disinfecting the floor and working 
benches in the laboratory. 
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2.3 Reagents and indicators 
2.3.1 Reagents 
2.3.1.1 Alpha-naphthol solution 
Alpha-naphthol was a product of British Drug House (BDH); London. This 
reagent was prepared as 5% aqueous solution and used for Voges-Proskauer 
(VP) test. 
 
2.3.1.2 Potassium hydroxide 
It was prepared as 40% aqueous solution and used for Voges-Proskauer test. 
 
2.3.1.3 Hydrogen peroxide 
This reagent was obtained from Agropharm Limited, Buckingham. It was 
prepared as 3% aqueous solution, and it was used for catalase test. 
 
2.3.1.4 Methyl red 
It was prepared by dissolving 0.04 g methyl red in 40 ml ethanol. The 
volume was made to 100 ml with distilled water. It was used for methyl red 
(MR) test. 
 
2.3.1.5 Tetra methyl-p-phenyl diamine dihydrocholoride 
This reagent was obtained from Hopkins and Williams; London. It was 
prepared at a concentration of 3% aqueous solution and was used to 
impregnate filter papers that were used for oxidase test. 
 
2.3.1.6 Nitrate test reagent 
Nitrate test reagent was composed of two solutions which were prepared 
according to Barrow and Feltham (1993). Solution A was composed of 
0.33% sulphanilic acid dissolved by gentle heating in 5N-acetic acid. 
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Solution B was composed of 0.6% dimethyl amine-alpha-naphthylamine 
dissolved by gentle heating in 5N-acetic acid. The reagent was used for 
nitrate reduction test. 
 
2.3.1.7 Kovac’s reagent 
This reagent was composed of para-dimethylaminobenzaldehyde, amyl 
alcohol and concentrated hydrochloric acid. It was prepared as described by 
Barrow and Feltham (1993) by dissolving the aldehyde (10 g) in the alcohol 
(150 ml) by heating in water bath; it was then cooled and the hydrochloric 
acid (50 ml) was added carefully. The reagent was stored at 4ºC for later use 
in indole test. 
 
2.3.2 Indicators 
2.3.2.1 Andrade‘s indicator 
It was composed of acid fuchsin (5 g), distilled water (1 liter) and 1N NaOH 
(150 ml).  It was prepared by dissolving the acid fuchsin in distilled water, 
and then 150 ml of alkali solution were added, mixed and allowed to stand at 
room temperature for 24 hours with frequent shaking until the colour 
changed from red to brown. It was used as indicator in sugar fermentation 
test. 
 
2.3.2.2 Bromothymol blue 
Bromothymol blue was obtained from BDH. The solution was prepared by 
dissolving 0.2 g of bromothymol blue powder in 100 ml distilled water. It 
was used as indicator in Hugh and Leifson’s (O/F) medium. 
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2.3.2.3 Phenol red 
Phenol red was obtained from Hopkins and Williams Ltd, London. It was 
prepared as 0.2% aqueous solution. It was used as pH indicator in urea agar 
medium. 
 
2.3.2.4 Lead acetate paper 
Filter paper strips, 4-5 mm wide and 50-60 mm long were impregnated in 
lead acetate saturated solution and then dried. It was used for hydrogen 
sulphide test. 
 
2.3.2.5 Bromocresol purple (BDH) 
Bromocresol purple indicator was prepared by dissolving 0.2 g of the 
powder in 100 ml distilled water. It was used as pH indicator in Hugh and 
Liefson’s (O/F) medium 
 
2.4 Preparation of Media for isolation, purification, identification and 
antibiotic sensitivity 
All media used in this study were obtained from Oxoid, England, unless 
otherwise specified. 
 
2.4.1 Peptone water 
This medium was prepared by dissolving 10 g peptone and 5 g sodium 
chloride in 1 liter of distilled water. The mixture was distributed in 5 ml 
volumes into clean bottles and sterilized by autoclaving at 1210C for 15 
minutes. 
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2.4.2 Peptone water sugars (Carbohydrate fermentation medium) 
Peptone water sugar medium contained 900 ml peptone water, 10 ml 
Andrade‘s indicator and 10 g sugar in 90 ml distilled water. The pH of 
peptone water was adjusted to 7.2 before the addition of Andrade‘s indicator 
and 10% sugar solution; the complete medium was well mixed, then 
distributed in portions of 5 ml into clean test tubes containing inverted 
Durham‘s tubes. The tubes were then autoclaved at 1150C for 20 minutes. 
The carbohydrates examined were glucose, sucrose, lactose, fructose, 
maltose, mannitol, xylose, sorbitol, malonate and salicin. 
 
2.4.3 Glucose-phosphate medium (MR-VP test medium)  
This medium was prepared by adding 7 g buffered peptone, 5 g dextrose and 
5 g dipotassium phosphate to 1 liter distilled water, then dissolved by 
steaming and then filtered. The pH was adjusted to 7.2, and then 5g of 
glucose were added and then mixed well. The complete medium was 
distributed into clean test tubes in 5 ml amounts. The medium was sterilized 
by autoclaving at 1150C for 15 minutes. 
 
2.4.4 Nutrient agar (plates and slants) 
This medium was prepared by adding 28 g of nutrient agar to 1 liter of 
distilled water and dissolved by boiling. The pH was adjusted to 7.2, and 
then sterilized by autoclaving at 1210C for 15 minutes. The prepared 
medium was distributed under aseptic condition in 20 ml volumes into 
sterile Petri dishes. For slants, the medium was distributed as 10 ml volumes 
in clean bottles and then put in a slope position to solidify. It was used for 
purification of isolates.   
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2.4.5 Blood agar  
2.4.5.1 Collection of blood  
Blood for Blood Agar medium was collected aseptically into sterile flask 
containing glass beads by vein puncture of jugular vein of healthy sheep 
kept for this purpose. The blood was defibrinated by shaking the flask after 
collection.  
Blood Agar medium was prepared by suspending 40 g of blood agar base in 
900 ml of distilled water and dissolved by boiling. The mixture was 
sterilized by autoclaving at 121oC for 15 minutes and cooled down to about 
50oC, and then the blood was added aseptically to make a final concentration 
of 10%. The prepared medium was mixed gently and distributed in 20 ml 
volumes into sterile Petri dishes. The poured plates were allowed to solidify 
on leveled surface. It was used for primary isolation purpose.  
 
2.4.6 MacConkey’s agar medium  
Fifty-two grams of MacConkey’s agar were dissolved in 1 liter distilled 
water. The pH was adjusted to 7.2, then the medium was sterilized by 
autoclaving at 121oC for 15 minutes and distributed in 20 ml volumes into 
sterile Petri dishes. The poured Petri dishes were allowed to solidify on flat 
surface. It was used for primary isolation purpose. 
 
2.4.7 Motility medium (Craigie tube medium) 
Thirteen grams of dehydrated nutrient broth were added to 5 g of Oxoid agar 
No.1 and dissolved in 1 liter of distilled water. The pH was adjusted to 7.2. 
The prepared medium was distributed in 5 ml volumes into clean test tubes 
which containing appropriate Craigie tubes and then sterilized by 
autoclaving at 121oC for 15 minutes. 
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2.4.8 Hugh and Liefson’s (O/F) medium 
This medium was prepared by dissolving 2 g of peptone powder, 5 g of 
sodium chloride, 0.3 g of potassium hypophosphate and 3 g of agar in 1 liter 
of distilled water. The pH was adjusted to 7.2 and bromocresol purple 
indicator was added. The complete medium was distributed into test tubes in 
5 ml amounts. The medium was sterilized by autoclaving at 115oC for 10 
minutes. 
 
2.4.9 Simmon’s citrate medium  
This medium was prepared by dissolving 17 g of the dehydrated medium in 
1 liter of distilled water. The dissolved medium was distributed in 10 ml 
volumes into clean bottles and sterilized by autoclaving at 121 0C for 15 
minutes and left to solidify in inclined position. 
 
2.4.10 Urea agar medium  
This medium was prepared by dissolving 2.4 g of the dehydrated medium in 
95 ml of distilled water by boiling. The dissolved medium was sterilized by 
autoclaving at 121 0C for 15 minutes, cooled to 50 0C, and then 5 ml of 
sterilized 40% urea solution were added under aseptic condition. The 
medium was then distributed in 5 ml volumes into sterile bottles and left to 
solidify in inclined position. 
 
2.4.11 Malonate–phenylalanine medium 
This medium was prepared by dissolving 2.0 g (NH4)2SO2, 0.6 g K2 HPO4, 
2.0 g NaCl,   3.0 g sodium malonate, 2.0 g D–L–phenylalanine and 1.0 g 
yeast extract in distilled water by heating and then filtered. The indicator 
solution was then added before sterilization by autoclaving at 115oC for 20 
min. 
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2.4.12 Starch agar 
10 g starch (potato starch) was triturated with 50 ml distilled water to a 
smooth cream then added to 1 liter nutrient agar medium and mixed. Then it 
was sterilized by autoclaving at 115oC for 10 minutes and distributed into 
Petri dishes as 15-20 ml volumes. 
 
2.5 Culture method 
2.5.1 Antibiotic preparations 
Ten milliliters of any sterile solution or suspension of an antibiotic were 
centrifuged (3000 rpm for 5 min) and then washed by using sterile normal 
saline for three times. After discarding of supernatant of last centrifugation 
and washing, the residual part was cultured on blood agar and MacConkey’s 
agar plates, and the plates were incubated at 37 oC for 48 hours. 
 
2.5.2 Non-antibiotic preparations 
Each non-antibiotic, sterile or non-sterile solution or suspension preparation 
was cultured by dispensing one ml from each sample on each of blood agar 
and MacConkey’s agar plates and rotated to cover the plate surface. Excess 
fluid was pippetted using a sterile Pasteur pipette and discarded. Plates were 
incubated for 48 hours at 37 oC. 
 
2.6 Isolation, purification and preservation of cultures 
After incubation period, each plate was observed for bacterial growth, 
different types of colonies and their morphological and biochemical 
properties. A part of a typical well separated colony was sub-cultured on 
Nutrient agar medium. The process of sub-culturing was repeated until pure 
cultures were obtained. Characteristics of pure isolates were observed and 
recorded. The purity of the culture was checked by examining Gram’s 
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stained smears. Pure culture was then inoculated into nutrient agar slant 
medium and incubated overnight at 37 0C. The pure culture was then stored 
at 4 0C for studying biochemical characteristics and antibiotic sensitivity of 
the isolates. 
 
2.7 Identification of isolates 
The purified isolates were identified according to criteria described by 
Barrow and Feltham (1993). This included staining reaction, cell 
morphology, growth condition, colonial characteristics, and growth reactions 
on different media and biochemical properties. 
 
2.7.1 Microscopic examination 
2.7.1.1 Staining  
Smears were prepared from all colony types during primary isolation or 
purification process. The smears were dried in the air and fixed by heating, 
stained by Gram’s method and examined under light microscope for 
presence of Gram-negative or Gram-positive bacteria (Cruickshank et al., 
1975). 
 
2.7.1.2 Gram’s method 
For the Gram’s stain, a four step process was followed after preparation, 
drying and fixation of smears:  
1. A primary stain (crystal violet) was applied for one minute. 
2. An iodine solution (acts as mordant: it causes the primary stain to 
adhere to the cells better) was applied for two minutes. 
3. Rinsed with acetone or 95% ethyl alcohol (decolorizer) for few 
seconds. 
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4. A counter stain (dilute carbol fuchsin) was applied for 0.5 minutes. 
Gram-positive cells retained the crystal violet stain. Gram-negative 
cells loosed the crystal violet during the decolorizing step and then 
colored by the counter stain.  
The smears were examined microscopically under oil immersion lens for 
cell morphology, cell arrangement and staining reaction. 
 
2.7.2 Biochemical methods for identification of isolated bacteria 
All biochemical tests were performed as described by Barrow and Feltham 
(1993); they included: 
 
2.7.2.1 Catalase test   
A drop of 3% H2O2 was placed on a clean slide and a colony of test culture 
on nutrient agar was picked by glass rod and added to the drop of H2O2. 
Positive reaction was indicated by immediate evolution of gas (air bubbles). 
 
2.7.2.2 Oxidase test 
A strip of filter paper soaked in 1% solution of tetramethyl-p-phenylene 
diamine dihydrocholoride and dried at 60o in hot air oven was placed on a 
clean glass slide by sterile forceps. A fresh test culture was put on the filter 
paper strip. If a purple color developed within 5-10 seconds, the reaction 
was considered positive. 
 
2.7.2.3 Oxidation fermentation (O/F) test     
Duplicate tubes of Hugh and Liefson’s medium were inoculated by stabbing 
with a straight wire. One of the tubes was sealed by a layer of sterile soft 
paraffin oil to protect it from air; both inoculated tubes were incubated at 37 
0C and examined daily for a period of fourteen days. Yellow color in open 
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tube indicated oxidative reaction, yellow color in both tubes indicated 
fermentation reaction.  
  
2.7 Motility test 
A motility medium tube was inoculated by stabbing with a straight wire into 
the center of the Craigie tube and then incubated at 37 0C for 24 hours. The 
organism was considered motile if there was turbidity in the medium in and 
outside the Cragie tube while the growth of non-motile organism confined 
inside Craigie tube. 
 
2.8 Sugar fermentation test  
Tubes of carbohydrate medium containing different sugars were inoculated 
with an overnight test culture, then incubated at 37 0C and examined daily 
for 7 days. The acid production (fermentation) was indicated by change in 
color to pink and gas production was indicated by presence of empty space 
in Durham‘s tube. 
 
2.9 Indole production test  
A fresh test culture was inoculated into peptone water and incubated at 37 0C 
for 48 hours. One ml Kovac‘s reagent was added to the tube. The appearance 
of a pink color in the reagent layer within a minute indicated positive 
reaction. 
 
2.10 Methyl red test 
The test culture was inoculated into glucose phosphate medium and then 
incubated at 37 0C for 48 hours. After incubation period, 2 ml of the broth 
culture were transferred into a clean test tube, and then two drops of methyl 
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red reagent were added and shaken well. Red color indicated positive 
reaction. Yellow or orange color indicated negative reaction. 
 
2.11 Voges-Proskauer test 
To the remaining part of broth culture of MR test, 0.6 ml of 5% alpha-
naphthol solution was added, followed by 0.2 of 40% KOH aqueous 
solution. The test tube was shaken well and kept at slant position for 30 min. 
Positive reaction was indicated by a strong red color. 
 
2.12 Citrate utilization test 
The test culture was inoculated onto Simmon‘s citrate medium, then 
incubated at 37 0C and examined daily for 7 days. Blue color indicated 
positive reaction. 
 
2.13 Hydrogen sulphide production 
A tube of peptone water was inoculated by the test organism and a lead 
acetate paper was inserted between the cotton plug and tube wall, then 
incubated at 37 0C and examined daily for a week. Blackening of paper 
indicated H2S production. 
 
2.14 Nitrate reduction test 
The nitrate broth was inoculated lightly and incubated for up to five days 
and 1 ml of reagent A was added followed by 1 ml of reagent B. A deep red 
color indicated that nitrate has been reduced to nitrite. To the tubes not 
showing a red colour within 5 minutes, powdered zinc was added and 
allowed to stand. Red colour indicated negative reaction. 
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2.15 Coagulase test  
The test was used for identification of Staphylococcus isolates. 
  
2.15.1 Slide coagulase test  
A colony of test culture was placed on a clean glass slide, emulsified in a 
drop of normal saline and then a loop-full of human plasma was added to 
bacterial suspension. Appearance of coarse microscopically visible clump 
was recorded as positive result. 
 
2.15.2 Tube coagulase test 
To 0.5 ml of 1:10 dilution of human plasma in normal saline, 0.5 ml of 18-
24 hour old broth culture of test organism was added, then incubated at 37 
0C and examined after 1, 3 and 24 hours for coagulation. Definite clot 
formation indicated positive result. 
 
2.16 Arginine medium 
This medium was prepared by dissolving 5 g of peptone powder, 5 g of yeast 
extract, 2 g of potassium hypophosphate, 0.5 g of glucose and 3 g Arginine 
monohydrochloride in 1 liter of distilled water. The pH was adjusted to 7.2. 
The medium was sterilized by autoclaving at 115oC for 20 minutes. The 
complete medium was distributed into test tubes in 5 ml amounts. 
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CHAPTER THREE 
RESULTS 
 
3.1 Overall isolates and source of isolation  
Out of 324 samples of open multiple-dose veterinary medical preparations 
(solutions and suspensions, sterile and non-sterile), 41 isolates were 
obtained. The isolates were recovered from 36 samples of various 
medication types, which represented 11.1% of the total samples. Five 
samples, which were collected from two dairy cattle farms, gave two 
isolates. All of the isolates were recovered from non-antibiotic preparations 
(sterile and non-sterile medicines) (Table 4). Twelve out of 22 medication 
types (54.5%) were found to be contaminated. As per medication type, 
antiparasitics, followed by vitamins were found most contaminated. They 
gave 28 isolates (68.3%) from 24 samples. Then anti-inflammatory drugs, 
which gave six isolates (14.6%) from five samples (Table 4). As per farm 
type (dairy or poultry), the contamination was found in 13 out of 30 dairy 
farms, whereas it was found in all poultry farms (Table 5). 
 
3.2 Identification of isolates 
3.2.1 Microscopic examinations 
Gram-stained smears of the pure isolates had differentiated the 41 isolates 
into 29 Gram-positive and 12 Gram-negative isolates (Table 6). 
 
3.2.2 Cultural and biochemical properties 
Cultural characteristics and biochemical testing (Tables 7, 8 and 9) were 
able to differentiate the isolates to a total of nine bacterial species, seven of 
them were Gram-positive types. Pseudomonas aeruginosa was the most 
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isolated species (10 times), followed by Staphylococcus aureus and Bacillus 
cereus (8 times each) (Table 6 10). 
 
 Isolation frequencies of other species were ranged between 1 and 5 times. 
Pseudomonas aeruginosa was isolated from 3.1% of total samples and 
constituted 24.4% of total isolates followed by B. cereus and S. aureus 
(2.5% of total samples and 8.1% of total isolates, for each) (Table 10). 
Isolation frequency and contamination rate of each drug by the various 
bacterial species is shown in Table 6. Pseudomonas aeruginosa was isolated 
from six drugs. Bacillus cereus and Staphylococcus aureus were isolated 
from five different drugs and Micrococcus luteus and Micrococcus varians 
were isolated from four drugs. Other species were isolated from 1-2 drugs. 
The bacterial types isolated from drug samples of poultry farms were B. 
cereus, P. aeruginosa and S. aureus. While all of the nine bacterial species 
were found in the samples from dairy farms.  
 
In relation to sterile and non-sterile medications, the non-sterile ones were 
found much more contaminated. Out of 13 non-sterile drug samples, 9 
(69.2%) were found to be contaminated, whereas out of 311 sterile drug 
samples, 27 (8.7%) were found to be contaminated. The sterile medications 
contained 225 antibiotic samples, which were all negative for bacterial 
growth. Of 86 sterile non-antibiotic preparations, 27 (31.4%) samples were 
found to be contaminated (Table 11). 
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3.3 Data on storage and handling methods of MDVs 
The questionnaire used to collect data on each drug showed that most drugs 
were not properly stored and administered. The majority of farms had no 
refrigerators air coolers or even cupboards for keeping medicines. In some 
farms medicines were found kept inside water. In some cases syringes were 
used for more than one time and animal. Also, no attention was paid to 
expiry dates and dates after which open vials should be discarded.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
50
Table 4. Bacterial contamination according to medication types 
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Antiparasitics 
  
  
  
  
Albendazole 9 6 66.7% 7 17.1% 
15 (36.7%)
  
  
  
  
Ivermectin 11 5 45.5% 5 12.2% 
Levamisole 1 1 100% 1 2.4% 
Nitroxinil 5 2 40% 2 4.9% 
Tetramizole 5 0 0 0 0 
Vitamins Vitamin 28 10 35.7% 13 31.7% 13 (31.7%)
Anti- 
inflammatories  
  
Dexamethasone 8 5 62.5% 6 14.6% 
6 (14.6%) 
  Phenylbutazone 15 0 0 0 0 
Antibiotics 
  
  
  
  
  
  
  
Amoxycillin 19 0 0 0 0 
0 
  
  
  
  
  
  
  
Ampicillin 3 0 0 0 0 
Enrofloxacin 29 0 0 0 0 
Gentamicin 15 0 0 0 0 
Oxytetracycline 71 0 0 0 0 
Procaine penicillin G 25 0 0 0 0 
Sulfadimidine 23 0 0 0 0 
Tylosin 40 0 0 0 0 
Antihistamines Diphenhydramine 1 1 100% 1 2.4% 1 (2.4%) 
Antipyretics Dipyrone 7 2 28.6% 2 4.9% 2 (4.9%) 
Local 
anesthetics Xylocaine 5 1 20% 1 2.4% 1 (2.4%) 
Metabolic 
 disease drugs 
Calcium 
borogluconate 1 1 100% 1 2.4% 1 (2.4%) 
Anti-bloat Methyl silikon 2 1 50% 1 2.4% 1 (2.4%) 
Disinfectants Hydrogen peroxide 1 1 100% 1 2.4% 1 (2.4%) 
Total   324 36  41    
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Table 5. Bacterial contamination according to farm type 
 
 
Dairy cattle 
farms 
Poultry 
farm 
Total no. 
(%) 
No. of tested farms 30 (85.7%) 5 (14.3%) 35 
No. of farms found with 
contaminated drugs 
13 (43.3%) 5 (100%) 18 (51.4%) 
No. of collected samples 303 (93.5%) 21 (6.5%) 324 
No. of contaminated samples 30 (9.3%) 6 (1.9%) 36 (11.1%) 
Types of sampled medications 21 (95.5%) 3 (13.6%) 22 
No. of bacterial isolates 35 (85.4%) 6 (14.6%) 41 
No. of bacterial species 8 (88.9%) 4 (44.4%) 9 
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Table 6. Bacterial species according to drug names  
Bacterial species Contaminated  drugs 
No. of collected 
samples No. of isolates 
Bacillus cereus 
 
 
 
 
Albendazole  9 2 
Ivermectin 11 2 
Vitamin 28 2 
Nitroxinil 5 1 
Dexamethasone 8 1 
Pseudomonas aeruginosa 
 
 
 
 
 
Nitroxinil 5 1 
Albendazole 9 2 
Levamisole 1 1 
Dexamethasone 8 1 
Ivermactin 11 1 
Vitamin 28 4 
Staphylococcus aureus 
 
 
 
 
Dexamethasone 8 2 
Hydrogen peroxide 3% 1 1 
Methyl silikon 2 1 
Albendazole 9 1 
Vitamin 28 3 
Micrococcus luteus 
 
 
 
Albendazole 9 1 
Diphenhydramine 1 1 
Ivermectin 11 1 
Vitamin 28 1 
Micrococcus varians 
 
 
 
Calcium borogluconate 1 1 
Dipyrone 7 1 
Xylocaine 5 1 
Dexamethasone 8 2 
Neisseria mucosa 
 
Albendazole 9 1 
Vitamin 28 1 
Staphylococcus haemolyticus 
 
Vitamin 28 1 
Dipyrone 7 1 
Staphylococcus auricularis Vitamin 28 1 
Staphylococcus epidermidis Ivermectin 11 1 
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Table 7. Biochemical properties of Staphylococcus spp. 
 
 
(+) = Positive; (-) = Negative; F = Fermentative; ND = Not done; VP =   
Voges-Proskauer 
 
 
 
 
Property S.  aureus S. epidermidis S. auricularis S. haemolyticus 
Shape Spherical Spherical Spherical Spherical 
Gram reaction + + + + 
Motility  Non-motile Non-motile Non-motile Non-motile 
Catalase  + + + + 
Oxidase  - - - - 
O/F F F F F 
VP + + + + 
Urease  + + - - 
Coagulase  + - - - 
Mannitol   + - - + 
Fructose  + + + + 
Lactose  + + - ND 
Maltose  + + + + 
Xylose  - - ND ND 
Sucrose + + + - 
Nitrate + + + + 
Arginine + + - - 
Trehalose + - ND ND 
Glucose ND ND - + 
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Table 8. Biochemical properties of Bacillus and Micrococcus spp. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(+) = Positive; (-) = Negative; F = Fermentative; ND = Not done; VP =   
Voges-Proskauer 
 
 
 
 
Property M. luteus M. varians B. cereus 
Shape Spherical Spherical Rod 
Gram reaction + + + 
Motility  Non-motile Non-motile Motile 
Catalase  + + ND 
Oxidase  + - + 
O/F O O ND 
VP - + + 
Urease  + + - 
Citrate ND ND - 
Coagulase  + - ND 
Fructose  - + ND 
Sucrose - - ND 
Nitrate -  + 
Arginine  - - ND 
Glucose - ND + 
Starch ND ND + 
Spore-shape   oval 
Indole ND ND - 
Growth on MacConkey’s Agar    + 
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Table 9. Biochemical properties of Gram-negative bacteria 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(+) = Positive; (-) = Negative; F = Fermentative; ND = Not done. 
 
 
 
Property Pseudomonas aeruginosa 
Neisseria 
mucosa 
Shape  Rod Spherical 
Gram reaction - - 
Motility Motile Non-motile 
Oxidase + + 
Catalase + + 
O/F O O 
Citrate + ND 
Urease + ND 
Glucose + + 
Lactose - - 
Fructose + ND 
Sucrose - + 
Mannitol + ND 
Maltose - + 
Starch hydrolysis - ND 
Casein hydrolysis + ND 
Nitrate + ND 
Arginine + ND 
Xylose + ND 
Arabinose + ND 
Growth on MacConkey’s Agar + ND 
Malonate + ND 
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Table 10. Overall isolation rate of bacterial species  
 
 
Organism 
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Percentage of isolation 
from 
Total 
samples
Non-antibiotic 
samples 
Pseudomonas aeruginosa 10 24.4% 3.1% 10.1% 
Bacillus cereus 8 19.5% 2.5% 8.1% 
Staphylococcus aureus 8 19.5% 2.5% 8.1% 
Micrococcus varians 5 12.2% 1.5% 5.1% 
Micrococcus luteus 4 9.8% 1.2% 4% 
Neisseria mucosa 2 4.9% 0.6% 2.1% 
Staphylococcus haemolyticus 2 4.9% 0.6% 2.1% 
Staphylococcus auricularis 1 2.4% 0.3% 1% 
Staphylococcus epidermidis 1 2.4% 0.3% 1% 
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Table 11. Level of contamination related to sterile and non-sterile 
veterinary medical preparations 
 
Samples 
  
Medication categories 
Sterile preparations 
Non-sterile 
preparations 
Sterile antibiotic 
preparations 
Sterile non-antibiotic 
preparations 
Total 
No. of collected 
samples 
225 86 311 13 
No. of contaminated 
samples 
0 27 27 9 
Percent of 
contamination 
0 31.4% 8.7% 69.2% 
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DISCUSSION 
 
Multi-dose vials of pharmaceutical preparations can offer potential 
advantages of cost effectiveness and convenience compared with single-dose 
vials; however the assumption that the content remains sterile after opening 
and through continued use is challenged by the literature (Melnyk et al., 
1993). Many illness outbreaks and individual cases in human were reported 
due to injection of MDVs contaminated medicines (Alter et al., 1983). 
However, with the exception of one Canadian (Sabino and Weese, 2006) and 
one American (Betbeze  et al., 2007) reports, this issue in veterinary filed 
was not found tackled before. The objective of this study was to investigate 
for the presence and type of bacterial contamination in multi-dose veterinary 
medication vials in dairy cattle and poultry farms of Khartoum State.  
 
This study demonstrated a high level of bacterial contamination in MDVs 
(11.1%), which is, apart from manufacturer’s error, attributed to mis-dealing 
and handling of multi-dose veterinary medication vials that was observed in 
the visited animal farms. Surprisingly, the contamination prevalence in 
parenteral non-antibiotic medications was 31.4% (27/86). Potential 
pathogenic bacteria were isolated from the test samples of injectable non-
antibiotic drugs. Each of these 27 contaminated sterile medications may be 
used for more than one animal, thus a large number of animals would be 
infected and this necessitates another type of treatment, which in turn may 
act as another source of infection and disease spread. The non-sterile 
preparations (oral and topical) showed the highest level of contamination 
(69.2%). Various species of bacteria, which comprised known toxinogenic 
and pathogenic bacteria, were isolated. However, the oral route is considered 
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far less risky than the parenteral one and it is like ingestion of contaminated 
food and water. This rate of contamination is considered high compared to 
contamination of MDVs in human medicine. Longfield et al. (1984) studied 
1223 samples from 864 MDVs and could not find any contamination, 
whereas the study reviewed other contamination studies with an overall 
contamination rate of 0.6% (24 contaminated vials out of 4036 samples). 
Melnyk (1993) reported a contamination rate of 1.4% (1 out of 69). 
Extrapolation of human results should be performed with care because of the 
differences in veterinary practices, environmental pathogen loads and drugs 
(Sabino and Weese, 2006). In veterinary medicine, only two reports were 
found. Sabino and Weese (2006) found a bacterial contamination prevalence 
of 18% (16/88). The second study (Betbeze et al., 2007) investigated 
bacterial contamination in a very small number of samples, only three multi-
dose ophthalmic solutions. Only Staphylococcus epidermidis was isolated. 
The two previous studies in veterinary field were carried out in veterinary 
hospitals, thus this study is the first study to be carried in animal farms. 
  
The antibiotic preparations were found free of bacterial contamination. Since 
the method of handling and use of MDVs for both antibiotic and non-
antibiotic preparations was the same, the antibiotics are supposed to be 
contaminated too, but the contaminating organisms were sensitive to the 
respective antibiotic, or the low centrifugation rate and the washing steps 
which were used to have antibiotic-free sediment and the culture method 
may not be efficient in recovery of cells. It was expected that, due to 
increased resistance to antibiotics, especially tetracycline and ß-lactam 
groups, we could isolate some resistant bacteria from antibiotics and then 
confirm there resistance to the respective antibiotic by conducting sensitivity 
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test. It was also expected that bacteria could be isolated if they were freshly 
introduced by, e.g., a contaminated needle that was used to inject blood 
infected animal. Bacteria were isolated before from antibiotics, e.g., Sabino 
and Weese (2006) (the first group of scientists investigated the microbial 
contamination in MDVs) were able to isolate Acinetobacter sp. from 2 
bottles containing antimicrobials (ceftiofur sodium and oxytetracycline). 
However, Longfield et al. (1984) was not able to isolate any bacteria from 
any kind of MDVs. Because antibiotics are more important and are the 
dominant type in animal farms, their samples constituted 69.4% of the 
collected samples. Non-antibiotic preparations (especially non-sterile ones) 
usually contain a bacteriostatic agent (preservative) to prevent bacterial 
contamination after opening the vial. However, if the manufacturer’s error is 
not considered, no preservative is effective against all kinds of bacteria 
(Wilson et al. 1998; Mattner and Gastmeier, 2004). Also the chemical 
substance of the preservative would have effect only after two hours (in 
average) on get in organisms (Wilson et al. 1998). So, if the drug is injected, 
orally dosed or topically applied, infection may occur. Some bacteria may be 
able to proliferate and produce toxins in the medications (Arduino, et al. 
1991). It is possible that endotoxins remain stable even after the preservative 
inactivates the organisms (Wilson et al., 1998). In addition, the poor storage 
conditions found in the visited farms and taking no care for expiry date and 
date of opening MDVs may justify the contamination found in the non-
antibiotic preparations. Viral agents were the most isolated microbes from 
MDVs in human medicine. Hepatitis C and B viruses, followed by HIV 
were especially reported (Plott, 1990; Thompson, 2009; Krause et al., 2000). 
This is due to the fact that bacteriostatic agents will destroy all introduced 
pathogenic virus and manufacturers recommend that only sterile equipment 
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is used to enter multidose vials (Wilson et al., 1998). So, viral contamination 
to MDVs is expected in animal medications too.  
Nine bacterial species were isolated from the MDVs in this study. Some of 
them, e.g. Staphylococcus aureus, Staphylococcus haemolyticus, 
Pseudomonas aeruginosa and Bacillus cereus are known human pathogens. 
It is conceivable that they could have the potential to cause serious 
bloodstream infections, either bacteraemia or septicemia.  Some of those 
bacteria were isolated before from MDVs for human medications: Mattner 
and Gastmeier (2004) isolated Staphylococcus epidermidis and (Bennett, et 
al. 1995) isolated Staphylococcus aureus. Pseudomonas aeruginosa was 
found causing fatal meningitis in two patients due to injecting them with 
contaminated medicine (Mattner and Gastmeier, 2004). Bacteria other than 
those of this study, which were reported as contaminants in multi-dose vials 
by other workers were Serratia marcescens, Klebsiella pneumoniae, group 
A Streptococcus, E. cloacae and C. albicans  (Mattner and Gastmeier, 2004; 
Bennett et al., 1995). 
  
The hygienic measures in the visited farms in this study were observed poor. 
They included bad storage condition, i.e. drugs are in most case not kept at 
their specified storage conditions, date of opening MDVs and their expiry 
dates are sometimes not considered and reusing of contaminated needles and 
syringes or dosing cups is common. All these things need to be corrected to 
prevent or reduce drug contamination. 
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Conclusions 
 
• The contamination prevalence was 11.1% of all samples and 36.4% in 
non-antibiotic samples of medication vials, which is considered a 
serious detection, especially potential pathogenic bacteria were found 
in injectable medications. 
• Various hygienic violations of using, handling and keeping MDVs, 
were encountered in the visited farms. 
   
Recommendations 
 
• Due to the recovery of potential pathogenic bacteria which can cause 
fatal systemic infection if a contaminated drug is injected, it is highly 
recommended that all hygienic measures concerned with MDVs to be 
strictly followed. 
• The role of veterinary extension should be made effective. 
• Medicines should be used under veterinary supervision. 
• A study to investigate viral contaminations in MDVs in animal farms 
was not carried out before, it is especially recommended because 
viruses are less affected by bacteriostatic and bactericidal agents than 
bacteria. 
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Questionnaire No. (   ) 
 
Sample serial no.:      ……………………………………………………… 
Farm location     :   .......................................................................................... 
Farm type           :   ………………….………………………………………. 
Herd size            : ……………………………………………………………. 
Phone   no.         :   ……………………………..…………………………….. 
Type and name of drugs commonly used: 
…………………………………………………………………………….….. 
……………………………………………………………………..…………
………...………………………………….…………………………………… 
Drugs used per month: 
 (a) Antibacterials:  .... ……………………………………............................. 
 (b) Antiparasitics: .......................................................................................... 
(d)  Others           : ........................................................................................... 
Storage condition of drugs: 
a- Refrigerator (     )      b- Cupboard / Shelf    (    ) 
c- Water           (     )               d- Others           (     ) 
Expiry date: 
 
a- Always considered           (   )    b- Not always considered    (   ) 
Opening date of vials: 
a- Always considered           (   )    b- Not always considered    (   )  
Checking for turbidity in vials: 
a- Yes                                  (   )             b- No                            (   ) 
If turbidity found: 
a- Drug is discarded           (    )             b- Drug is not discarded 
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Syringe:  
a- Always sterile (   ) b- Reused after boiling (   ) c- Reused without boiling  
Reusing of non-sterile syringe: 
a-For the same animal          (   )             b- Different animal         (   ) 
c- One drug                       (   )            d- More than one drug     (   ) 
Data specific to drugs: 
Name of drug: ……………………… Form (conc): …………………..…….. 
Route of Administration:…………..   Storage place: …………………….. 
Manufacture date:   ……………         Purchasing date………………….…….. 
Expiry date……………………...      When opened:…………………. 
 
Closure: 
a- Well closed                    (   )             b- Leaking                          (   ) 
Clearness 
a- Turbid                   (   )            b- Dirty (  )      c- Clear         (   ) 
 
 
 
 
 
 
